Inventor · disambiguated record
Stéphanie Cornen
Also filed as: CORNEN STEPHANIE · CORNEN STÉPHANIE
6 granted patents·5 pending applications·22 citations·filing 2015–2023
77Inventor score
Files withINNATE PHARMA11
Top patents by PatentIndex Score
11 records- 0194US10577419B2KIR3DL2 binding agentsINNATE PHARMA·Filed 2015·Granted Mar 3, 2020·15 cites·10 claims
- 0288US11858990B2KIR3DL2 binding agentsINNATE PHARMA·Filed 2020·Granted Jan 2, 2024·2 cites·7 claims
- 0387US11078274B2Siglec neutralizing antibodiesINNATE PHARMA·Filed 2017·Granted Aug 3, 2021·3 cites·23 claims
- 0480US2024124579A1Kir3dl2 binding agentsINNATE PHARMA·Filed 2023·Application pending·0 cites
- 0578US11623954B2Siglec-9-neutralizing antibodiesINNATE PHARMA·Filed 2018·Granted Apr 11, 2023·1 cites·12 claims
- 0672US11083785B2Siglec-10 antibodiesINNATE PHARMA·Filed 2016·Granted Aug 10, 2021·1 cites·9 claims
- 0769US2023085847A1Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancerINNATE PHARMA·Filed 2022·Application pending·0 cites
- 0868US2021363249A1Siglec neutralizing antibodiesINNATE PHARMA·Filed 2021·Application pending·0 cites
- 0960US2024199750A1Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engagingINNATE PHARMA·Filed 2022·Application pending·0 cites
- 1056US11447545B2Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancerINNATE PHARMA·Filed 2018·Granted Sep 20, 2022·0 cites·14 claims
- 1137US2017306014A1Cross reactive siglec antibodiesINNATE PHARMA·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →